“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...
In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s ...
Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. | Amid a dramatic reshaping of the federal ...
It's not yet been a week since Marty Makary, M.D., was confirmed to lead the FDA as its commissioner. | Peter Marks, M.D., Ph ...
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
After a Houston judge denied Johnson & Johnson’s third attempt to resolve approximately 90,000 talcum powder lawsuits through ...
Patients are looking to pharmaceutical companies to offer healthcare services beyond just drug development, and, ideally, in ...
Lilly continues full-court press against breast cancer with women's March Madness event sponsorships
As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback